 Doc and vaccine maker Moderna faded today following new data showing fading effectiveness of its RSV shot. Shares fell 11% after the CDC said Moderna's vaccine dropped from 55% efficacy over the first year to just 36 in the second. That compares to Pfizer's RSV shot, which has 74% efficacy in the second year and GlaxoSmithKline's 59% second year efficacy.